Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biosimilars: recent developments.

A Covic1, M K Kuhlmann

  • 1Dialysis and Transplantation Centre, C.I. Parhon University Hospital, Iasi 700503, Romania. acovic@xnet.ro

International Urology and Nephrology
|March 3, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Renin-angiotensin system and cancer: epidemiology, cell signaling, genetics and epigenetics.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2020
Same author

Body composition and circulating estradiol are the main bone density predictors in healthy young and middle-aged men.

Journal of endocrinological investigation·2018
Same author

Kidney transplantation in Romania: two transplant centers experience.

International urology and nephrology·2017
Same author

A Rare Clinical Course of Seronegative Pulmonary-Renal Syndrome.

Case reports in critical care·2016
Same author

Calibrating the impact of dual RAAS blockade on the heart and the kidney - balancing risks and benefits.

International journal of clinical practice·2016
Same author

Interchangeability among reference insulin analogues and their biosimilars: regulatory framework, study design and clinical implications.

Diabetes, obesity & metabolism·2016
Same journal

From static risk prediction to actionable nutritional surveillance in peritoneal dialysis.

International urology and nephrology·2026
Same journal

Correction: Expression analysis of epithelial membrane protein 1 (EMP1) gene in kidney stone patients.

International urology and nephrology·2026
Same journal

Is time in range an independent predictor of early diabetic kidney disease beyond HbA1c?

International urology and nephrology·2026
Same journal

Association between 24-h proteinuria and phenotypic age acceleration in adults with preserved kidney function: a cross-sectional study.

International urology and nephrology·2026
Same journal

Predictors of residual tumour and recurrence in high-grade NMIBC: insights from a multicenter re-TURBT cohort.

International urology and nephrology·2026
Same journal

Systematic review and meta-analysis of randomized controlled trials: low-intensity extracorporeal shockwave therapy (Li-ESWT) for erectile dysfunction after radical prostatectomy.

International urology and nephrology·2026
See all related articles

Biosimilars, follow-on protein drugs, are emerging as patents expire for originator biopharmaceuticals. Ensuring their safety and comparability, especially regarding immunogenicity, is crucial for regulatory approval.

Area of Science:

  • Biotechnology and Pharmaceutical Sciences
  • Drug Development and Regulation

Background:

  • Biopharmaceuticals, complex recombinant protein drugs, have transformed disease treatment.
  • Expiring patents for originator biopharmaceuticals are driving the development of biosimilars.
  • Biosimilars are perceived as cost-effective alternatives, but manufacturing complexities raise concerns.

Purpose of the Study:

  • To review biopharmaceutical production processes.
  • To discuss potential long-term safety issues associated with biopharmaceuticals.
  • To highlight regulatory challenges in approving new biosimilar molecules.

Main Methods:

  • Literature review of biopharmaceutical production.
  • Analysis of safety and comparability concerns for biosimilars.

Related Experiment Videos

  • Examination of regulatory frameworks for biosimilar approval.

    • Main Results:

    • Biopharmaceutical production is complex, making identical copies impossible.
    • Protein molecule complexity raises questions about biosimilar safety and immunogenicity.
    • Regulatory bodies face challenges in establishing guidelines for biosimilar evaluation.

    Conclusions:

    • The complexity of biopharmaceuticals necessitates rigorous evaluation of biosimilars.
    • Immunogenicity remains a key safety concern for follow-on protein products.
    • Clear regulatory pathways are essential for the safe introduction of biosimilars.